ArticleExpert review of molecular diagnostics2014
A microRNA meta-signature for pancreatic ductal adenocarcinoma.
Article in Expert review of molecular diagnostics, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 1 synthesis or guideline pooled it, 34 citations in OpenAlex.
- Systematic Review and Meta-Analysis of Diagnostic Accuracy of miRNAs in Patients with Pancreatic Cancer.Disease markers · 2018Pooled it
- The miR-1305/KLF5 negative regulatory loop affects pancreatic cancer cell proliferation and apoptosis.Human cell · 2025Article
- Review
- Review
- Recent Advances in Pancreatic Cancer: Novel Prognostic Biomarkers and Targeted Therapy-A Review of the Literature.Biomolecules · 2021Review
- Current State of "Omics" Biomarkers in Pancreatic Cancer.Journal of personalized medicine · 2021Review
- Article
- Review
- Pancreatic Cancer Heterogeneity Can Be Explained Beyond the Genome.Frontiers in oncology · 2019Review
- Non-Coding RNAs and Resistance to Anticancer Drugs in Gastrointestinal Tumors.Frontiers in oncology · 2018Review
- Tissue MicroRNA profiles as diagnostic and prognostic biomarkers in patients with resectable pancreatic ductal adenocarcinoma and periampullary cancers.Biomarker research · 2017Article
- Article
- Developments in miRNA gene signaling pathways in pancreatic cancer.Future oncology (London, England) · 2016Review
- Association of Fusobacterium nucleatum with immunity and molecular alterations in colorectal cancer.World journal of gastroenterology · 2016Review
- MicroRNA-153 is a prognostic marker and inhibits cell migration and invasion by targeting SNAI1 in human pancreatic ductal adenocarcinoma.Oncology reports · 2015Article
- Association of Fusobacterium species in pancreatic cancer tissues with molecular features and prognosis.Oncotarget · 2015Article
- Late-phase miRNA-controlled oncolytic adenovirus for selective killing of cancer cells.Oncotarget · 2015Article
- Clinical implications of miRNAs in the pathogenesis, diagnosis and therapy of pancreatic cancer.Advanced drug delivery reviews · 2015Review
- MicroRNA profiling of primary pulmonary enteric adenocarcinoma in members from the same family reveals some similarities to pancreatic adenocarcinoma-a step towards personalized therapy.Clinical epigenetics · 2015Article
- Molecular mechanisms underlying the role of microRNAs in the chemoresistance of pancreatic cancer.BioMed research international · 2014Review
Corrections and comments
- Comment on
Authors and funding
8 authors at 3 institutions in 2 countries.
Funding
Abstract
Due to its aggressive and late presentation, there is an urgent need for novel and reliable biomarkers for the diagnosis and prognostication of pancreatic ductal adenocarcinoma (PDAC). MiRNAs have been extensively profiled in PDAC tissues, biopsies, blood samples and other biofluids and their expression levels compared to normal and chronic pancreatitis (CP) specimens in order to identify the most relevant candidates. Consolidation of these activities has not been attempted until now. The evaluated meta-review by Ma et al. helps to define the use of miRNAs as biomarkers for detecting this tumor-type and predicting survival outcomes in PDAC. Based on frequency and consistency between microarray studies, they identified a miRNA meta-signature for recognising PDAC: upregulation of miR-21, 23a, 31, 100, 143, 155, and 221; with downregulation of miR-148a, 217 and 375. Furthermore, they validated high miR-21, high miR-31 and low miR-375 tumoural expression as independently prognostic for poor overall-survival (OS; n = 70).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.